Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer

BACKGROUND: Canfosfamide is a novel glutathione analog activated by glutathione S-transferase P1-1. This study evaluated the safety and efficacy of canfosfamide in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum resistant ovarian cancer. Patients with platinum resist...

Descripción completa

Detalles Bibliográficos
Autores principales: Kavanagh, John J, Levenback, Charles F, Ramirez, Pedro T, Wolf, Judith L, Moore, Carla L, Jones, Marsha R, Meng, Lisa, Brown, Gail L, Bast, Robert C
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2851575/
https://www.ncbi.nlm.nih.gov/pubmed/20222977
http://dx.doi.org/10.1186/1756-8722-3-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2851575/
https://www.ncbi.nlm.nih.gov/pubmed/20222977
http://dx.doi.org/10.1186/1756-8722-3-9

Ejemplares similares